RxDoctor Payments Data

Sunil Patel, MD

Internal Medicine · Newark, NJNPI 1134256936

Payments from drug & device makers

$2,752in general payments, 2019–2025

Across 31 payments — averaging $88.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • TG Therapeutics, Inc.$287
  • E.r. Squibb & Sons, L.L.C.$259
  • Pfizer$159
  • AstraZeneca$140
  • Novo Nordisk$129
  • plus $397 from 6 others

What the payments were for

  • Consulting fees$1,23045%
  • Travel & lodging$28710%
  • Food & beverage$1,23545%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,752 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$118,864
Medicare patients
274
Services billed
1,477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate26$96,630
EliquisApixaban310$84,211
Invega SustennaPaliperidone Palmitate12$44,398
TivicayDolutegravir Sodium39$43,552
EntrestoSacubitril/Valsartan122$40,243
XareltoRivaroxaban137$39,302
JardianceEmpagliflozin115$35,947
ActemraTocilizumab24$29,876
TrulicityDulaglutide32$29,044
JanuviaSitagliptin Phosphate93$26,655
DescovyEmtricitabine/Tenofov Alafenam11$25,629
SantylCollagenase Clostridium Hist.16$22,321
Atorvastatin Calcium978$16,901
LinzessLinaclotide24$13,811
Divalproex Sodium287$10,945

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$159$84,211310 claims
Johnson & JohnsonInvega Sustenna, Xarelto$15$83,700149 claims
NovartisEntresto$112$40,243122 claims
GSKBreo Ellipta, Incruse Ellipta, Trelegy Ellipta, Anoro Ellipta$108$33,86872 claims
GileadDescovy$1,381$25,62911 claims
AstraZenecaFarxiga, Symbicort$140$19,10468 claims
Novo NordiskFiasp$129$9,07929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Newark

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →